미국 · 보도자료 · Kyverna Therapeutics, Inc. · 2026-10-07 12:00
키베르나, 강직인간증후군·다발성경화증 임상 긍정적 데이터 발표 예정
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS
